adjuvant therapy

An additional treatment given after the primary treatment to lower the risk of the disease returning.

Adjuvant therapy refers to secondary treatments given after the primary treatment (usually surgery) to lower the risk of the disease returning. In biotechnology and healthcare investing, this term is most frequently encountered in oncology, where treatments like chemotherapy, radiation, hormone therapy, or personalized cancer vaccines are administered to target remaining microscopic cancer cells that cannot be detected by scans. For biotech investors, clinical trial data in the adjuvant setting is a major catalyst. Developing a drug that successfully moves from treating late-stage metastatic disease into the adjuvant setting is highly lucrative. Because adjuvant patients are treated earlier in their disease progression and with curative intent, they typically undergo longer treatment durations and represent a significantly larger patient population. When evaluating clinical trials for adjuvant therapies, investors look closely at endpoints like disease-free survival (DFS) or recurrence-free survival (RFS) rather than overall survival (OS) alone. A key pitfall for investors is assuming that success in late-stage metastatic trials will automatically translate to the adjuvant setting; the biology of early-stage microscopic disease can differ, and the safety tolerance for adjuvant treatments is much lower because these patients are often otherwise healthy and potentially cured.

A biotechnology company evaluates its new oncology drug in a Phase 3 adjuvant trial. Out of 500 patients who underwent surgery, 250 received the adjuvant drug and 250 received a placebo. Over 3 years, 35 patients in the drug group experienced cancer recurrence compared to 70 in the placebo group, demonstrating a 50% reduction in the risk of recurrence (35 / 70 = 0.50).